Clinical Trial

A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden

Study acronym: ADsolve
Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The purpose of this study is to measure how well taking lebrikizumab alone works for participants with fewer places on the body with eczema (atopic dermatitis), but these places may be very itchy. Participation in this study will last up to approximately 38 weeks (9 and a half months) including 24 weeks (6 months) of treatment.
Protocol Amendment History 4 changes
critical Trial status changed: RECRUITING → ACTIVE_NOT_RECRUITING 2026-05-23
notable Enrollment increased: 200 -> 233 participants 2026-05-23
notable Primary completion pushed: 2026-04 -> 2026-05-14 2026-05-23
notable Trial sites reduced: 71 -> 66 locations 2026-04-18
Trial Details
NCT Number NCT07006792
Lead Sponsor Eli Lilly and Company
Conditions Atopic Dermatitis
Enrollment 233 participants
Start Date 2025-06-16
Primary Completion 2026-05-14 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2026-05-22